MedTrace Logo

Real World Outcomes Using Novel Agents for AML in the UK

NCT05312112 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2023-03-02

No results posted yet for this study

Summary

This project will collect data on patients with acute myeloid leukemia in the United Kingdom who were treated with two new targeted therapies during the coronavirus pandemic

Conditions

Interventions

DRUG

Venetoclax

Observational study of venetoclax in AML

DRUG

Gilteritinib

Observational study of gilteritinib in AML

Sponsors & Collaborators

Principal Investigators

  • Richard Dillon · King's College London

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2023-10-01
Completion
2023-10-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05312112 on ClinicalTrials.gov